Morningstar - DaVita Inc. (DVA) DaVita Announces Changing of the Guard: Thiry to Leave CEO Post After Nearly 20 Years

Report

Morningstar

Jake Strole

EUR 100.00 For Business Accounts Only

DaVita Announces Changing of the Guard: Thiry to Leave CEO Post After Nearly 20 Years

On April 29, narrow-moat DaVita announced the departure of CEO Kent Thiry effective June 1, 2019, although he will remain on the board as executive chairman until June 2020. The board has appointed Javier Rodriguez, the current CEO of DaVita's kidney care operations, to lead the firm. Rodriguez is an obvious successor, in our view, with over 20 years' experience at DaVita in various leadership positions including heading up the company's core dialysis business since 2014. We don't expect this de...

29/04/2019 14 EN

Underlying

DaVita Inc.

DaVita is a healthcare provider focused on transforming care delivery to improve quality of life for patients. The company's United States dialysis business provides kidney dialysis services for patients suffering from end stage renal disease (ESRD). The company's dialysis services include outpatient hemodialysis services, hospital inpatient hemodialysis services, home-based dialysis services, ESRD laboratory services, and management services. The company's ancillary services and strategic initiatives businesses include disease management services, physician services, ESRD Seamless Care Organization joint ventures, clinical research programs, vascular access services, as well as international dialysis operations.

See profile

US23918K1088 New York Stock Exchange United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Jake Strole

Other Reports on these Companies

Moody's Investors Service

Moody's Ratings assigns Ba3 rating to DaVita's proposed senior unsecured notes

Moody's Ratings (Moody's) assigned a Ba3 rating to DaVita Inc.'s ("DaVita" or "the company") proposed senior unsecured notes. There is no change to the company's existing ratings, including the Ba2 corporate family rating (CFR), Ba2-PD probability of default rating (PDR), Ba1 senior secured bank cre...

EUR 152.82

May 20, 2025 May 20, 2025 1 EN

Moody's Investors Service

DaVita Inc.: Update to credit analysis

Our credit view of this issuer reflects its strong free cash flow and its considerable scale and strong US market position, against its track record of debt-funded share repurchases.

EUR 212.25

January 24, 2025 January 24, 2025 1 EN

Moody's Investors Service

Moody's Ratings announces completion of a periodic review of ratings of DaVita Inc.

Moody's Ratings (Moody's) has completed a periodic review of the ratings of DaVita Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 15 January 2025 in which we reassessed the appropriateness of the ratings in the context of the...

January 21, 2025 January 21, 2025 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

DaVita Announces Changing of the Guard: Thiry to Leave CEO Post After Nearly 20 Years

Moody's Ratings assigns Ba3 rating to DaVita's proposed senior unsecured notes

DaVita Inc.: Update to credit analysis

Moody's Ratings announces completion of a periodic review of ratings of DaVita Inc.

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe